Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751992 · ClinicalTrials.gov registry record · Phase 4
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
A Phase 4 study of Kidney Transplant Recipients and Old Age, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT06751992 is a Phase 4 study of Kidney Transplant Recipients and Old Age that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 92 participants, above the 55-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06751992, a Phase 4 study of Kidney Transplant Recipients and Old Age, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
Conditions Studied
Interventions
- DRUG Conversion to extended-release tacrolimus
- DRUG Maintenance of immediate-release tacrolimus
Study Locations (1)
Massachusetts
- MGH Kidney Transplant Clinic - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2026-03-17 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06751992
The ClinicalTrials.gov registry entry for NCT06751992 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (67% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Transplant Recipients appearing as the primary indexed condition, and to 2 interventions - of which Conversion to extended-release tacrolimus is the first listed.
NCT06751992 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06751992 about?
NCT06751992 is a clinical study titled "Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients". The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
What is the current status of trial NCT06751992?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2026-03-17. Estimated completion is 2027-10-01.
What conditions does trial NCT06751992 study?
This clinical trial studies the following conditions: Kidney Transplant Recipients, Old Age.
What interventions are being tested in trial NCT06751992?
The interventions under investigation include: Conversion to extended-release tacrolimus (DRUG), Maintenance of immediate-release tacrolimus (DRUG).
Who is sponsoring clinical trial NCT06751992?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751992 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
COMPLETED · Phase 4
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
-
COVID Protection After Transplant-Immunosuppression Reduction
COMPLETED · Phase 2
-
COVID-19 Protection After Transplant Pilot Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.